metastasis-free survival

ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

Staff Reporter September 13, 2023 0

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates...

European Medicines Agency Validates Type II Variation for Astellas’ XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

WS Audiology Strengthens Commitment to Innovation with New R&D Centre of Excellence in Hyderabad

TOP PMR SPECIALIST DR. AASTIK BHATT JOINS HCAH

1 IN 6 INDIVIDUALS STRUGGLE WITH INFERTILITY

Exactech Enhances High Technology Knee System with New Balancing Software

BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000

European Medicines Agency Validates Type II Variation for Astellas’ XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

Interesting Stories For You

WS Audiology Strengthens Commitment to Innovation with New R&D Centre of Excellence in Hyderabad

TOP PMR SPECIALIST DR. AASTIK BHATT JOINS HCAH

1 IN 6 INDIVIDUALS STRUGGLE WITH INFERTILITY

Exactech Enhances High Technology Knee System with New Balancing Software

BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000